Cymbalta Receives FDA Nod for Chronic Musculoskeletal Pain Management

8 November 2010 (Last Updated November 8th, 2010 18:30)

Eli Lilly and Company has received approval from the US Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) to manage chronic musculoskeletal pain. It has been established in studies that Cymbalta significantly reduced chronic low back pain and chronic pain due to osteoart

Eli Lilly and Company has received approval from the US Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) to manage chronic musculoskeletal pain.

It has been established in studies that Cymbalta significantly reduced chronic low back pain and chronic pain due to osteoarthritis.

Cymbalta is a non-narcotic pain reliever and is indicated to be taken daily by people with chronic pain.

Although the exact mechanism in which Cymbalta reduces chronic musculoskeletal pain is not known, it is believed that Cymbalta works by enhancing the body's natural pain suppressing system.